Compare Capri Holdings Ltd (CPRI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Viatris Inc — how do they compare? Capri Holdings Ltd trades at $15.62 (market cap $1.75B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 10.7× Capri Holdings Ltd's market cap, and Viatris Inc pays a 2.95% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals.
| CPRI | VTRS | |
|---|---|---|
Market Cap | $1.75B | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $17.86 |
52-Week Low | $14.98 | $9.49 |
Enterprise Value | $3.03B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $15.43, down 65% over five years but showing recent earnings momentum with three consecutive quarterly beats. The stock faces bearish technical signals with moving averages indicating downward pressure, while fundamentals reveal declining revenue from $5.7B in 2022 to $4.4B in 2025 and a significant net loss of -$1.18B. Analyst consensus sits at $19.60 with mixed ratings (44% Buy, 52% Hold), reflecting cautious optimism about the company's turnaround strategy post-Versace sale.
The investment case hinges on CPRI's ability to stabilize Michael Kors and grow Jimmy Choo profitability, but risks include ongoing revenue declines, luxury market softness, and high debt levels. With the current price near 52-week lows and 27% upside to consensus target, the stock offers potential for recovery if management executes its revamp plans successfully, though macroeconomic headwinds and brand challenges remain significant concerns.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
